Durvalumab is a drug that works by inhibiting the PD-L1 protein and stimulating the cells of the immune system to act against tumor cells.
Durvalumab is given intravenously every 2 weeks for a total of 12 months at a dose of 10 mg / kg body weight.
What are the potential side effects of Durvalumab?
Like all medicines, it can cause side effects, although not everybody gets them.
Durvalumab acts on the immune system and can cause inflammation in some parts of the body. Inflammation can cause serious damage to the body and some inflammatory conditions can be life-threatening and require treatment or discontinuation of durvalumab.
Among the side effects observed:
- Muscular or joint pain or weakness
- Skin reactions and lesions (increased vitiligo)
- Abdominal pain
- Lack of appetite
- Skin itching
- Shortness of breath or wheezing
- Abnormalities in thyroid function tests
– Immunotherapy for lung cancer
– NSCLC therapeutic approach: PACIFIC study